HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies

A significant shift in the ownership structure of pharmaceutical player Corona Remedies Limited occurred on June 17, 2026, as major institutional investors stepped in to acquire a substantial stake. This massive block deal marks a key movement in the healthcare sector, involving some of the world’s most prominent asset management firms.

Massive Divestment by Sepia Investments and Anchor Partners

The block deal was headlined by Sepia Investments, which offloaded 43,28,943 shares of Corona Remedies. Executed at a price of ₹1,730 per share, the transaction by Sepia alone amounted to approximately ₹748.9 crore. Adding to the sell-side momentum, Anchor Partners also divested its holdings, selling 1,61,861 shares at the same price point, worth roughly ₹28 crore.

In total, these two sellers successfully exited or reduced their positions by offloading shares worth approximately ₹776.9 crore in the pharmaceutical company, signaling a major liquidity event in the stock.

HDFC Mutual Fund Dominates the Buy Side

While the sell-side was concentrated among two entities, the buy-side saw intense participation from twelve different institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, single-handedly absorbing more than half of the total deal value. HDFC MF acquired 24,50,000 shares, an investment totaling roughly ₹423.9 crore.

Other heavyweight domestic and international players also secured significant positions:

• Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
• Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares valued at ₹78 crore.
• Invesco Mutual Fund: Acquired 2,89,017 shares for approximately ₹50 crore.
• Kotak Mahindra Mutual Fund: Picked up 1,61,861 shares worth ₹28 crore, a volume that exactly matched the quantity sold by Anchor Partners.

Global Institutional Interest in Corona Remedies

The deal also highlights growing interest from global sovereign wealth funds and specialized emerging market funds. The Abu Dhabi Investment Authority (ADIA) participated in the deal, purchasing 39,130 shares worth approximately ₹6.8 crore.

Ayrıca, Ashoka WhiteOak Emerging Markets Equity Fund'un 1.48.686 hisse (25,7 crore ₹) ve WhiteOak Capital Mutual Fund'un 145.000 hisse (25,1 crore ₹) satın almasıyla WhiteOak grubu önemli bir kararlılık sergiledi. Diğer katılımcılar arasında Aberdeen Standard Sicav I, India Acorn ICAV ve Factory Mutual Insurance Company'nin yer alması, şirkete 1.730 ₹ fiyat seviyesindeki geniş tabanlı kurumsal güvenin altını çizdi.

Önemli Çıkarımlar

• Büyük Pay Devri: Sepia Investments ve Anchor Partners, bir blok anlaşma aracılığıyla Corona Remedies'de toplamda yaklaşık 776,9 crore ₹ tutarında pay devretti.
• Lider Alıcı Olarak HDFC MF: HDFC Mutual Fund, 24,5 lakh hisse için 423,9 crore ₹ yatırım yaparak işlemin değerinin %50'sinden fazlasını temsil eden ana alıcı oldu.
• Geniş Kurumsal İlgi: İşleme, büyük Hint yatırım fonlarının yanı sıra ADIA ve Aberdeen gibi küresel devleri de içeren 12 yatırımcıdan oluşan çeşitli bir grup katıldı.